Cyclopharm (CYC) has a market capitalization of approximately A$69M, trading at A$0.55 on the ASX. Market cap moves with the live share price.
Cyclopharm's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Cyclopharm runs a net profit margin of -53.3%, a gross margin of 24.1%, and an operating margin of -56.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Cyclopharm reported revenue of A
Cyclopharm does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Cyclopharm carries a debt-to-equity ratio of 0.55x and a current ratio of 2.53x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cyclopharm (CYC) the key facts are: market cap A$69M, revenue A
Get Cyclopharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.